Streptozotocin-induced beta-cell death is independent of its inhibition of O-GlcNAcase in pancreatic Min6 cells.
Streptozotocin (STZ) injection into experimental animals selectively causes massive beta-cell death. The mechanism of this specific toxicity is not fully understood. Recently, it has been discovered that O-linked N-acetylglucosamine (O-GlcNAc) is enriched in the beta-cells. It has been proposed that STZ toxicity may be due to its inhibition of neutral O-GlcNAcase activity, the enzyme that removes O-GlcNAc from cytosolic proteins (K. Liu et al., 2000, Proc. Natl. Acad. Sci. USA 97, 2820-2825). To further ascertain the role of O-GlcNAcase in beta-cell death, we have used PUGNAc, a potent and specific O-GlcNAcase inhibitor, together with STZ in pancreatic Min6 cells. Both STZ and PUGNAc increased O-GlcNAc to similar levels on intracellular proteins. STZ, but not PUGNAc, decreased cellular protein synthesis by 66.0% within 8 h, killed 80.9% of the cells within 18 h, and decreased insulin secretion. STZ, but not PUGNAc, also caused genomic DNA fragmentation, suggesting that some of the cells were undergoing apoptosis. Prolonged treatment with PUGNAc (72 h) maintained high intracellular O-GlcNAc levels, but did not result in any apparent cell damage. Furthermore, the toxicity of STZ can be largely reversed by 3-aminobenzamide, a poly(ADP-ribose) polymerase inhibitor. These data strongly indicate that STZ-induced beta-cell death is not caused by elevated intracellular O-GlcNAc levels, but instead likely involves poly(ADP-ribose) polymerase in the mechanism.
Gao
Y
Y
Department of Biological Chemistry, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205-2185, USA.
Parker
G J
GJ
Hart
G W
GW
D000117:Acetylglucosamine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D000118:Acetylglucosaminidase / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001549:Benzamides / Q000494:pharmacology; D015153:Blotting, Western; D001921:Brain / Q000201:enzymology; D002417:Cattle; D016923:Cell Death / Q000187:drug effects*; D002460:Cell Line; D002467:Cell Nucleus / Q000201:enzymology; D053938:DNA Fragmentation / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D051548:Histone Acetyltransferases; D015151:Immunoblotting; D007328:Insulin / Q000378:metabolism; D007515:Islets of Langerhans / Q000166:cytology* / Q000201:enzymology*; D051379:Mice; D009097:Multienzyme Complexes; D010091:Oximes / Q000737:chemistry / Q000494:pharmacology; D010179:Pancreas / Q000201:enzymology* / Q000378:metabolism; D048448:Phenylcarbamates; D011065:Poly(ADP-ribose) Polymerases / Q000378:metabolism; D013311:Streptozocin / Q000737:chemistry / Q000494:pharmacology*; D013997:Time Factors; D001619:beta-N-Acetylhexosaminidases
D001549:Benzamides; D007328:Insulin; D009097:Multienzyme Complexes; D010091:Oximes; D048448:Phenylcarbamates; C068836:N-acetylglucosaminono-1,5-lactone O-(phenylcarbamoyl)oxime; D013311:Streptozocin; C025160:3-aminobenzamide; D051548:Histone Acetyltransferases; D011065:Poly(ADP-ribose) Polymerases; C110628:hexosaminidase C; D000118:Acetylglucosaminidase; D001619:beta-N-Acetylhexosaminidases; D000117:Acetylglucosamine